Abstract
BackgroundExperimental therapies that target the immune system have expanded greatly in recent years due to the success of immune checkpoint inhibitory antibodies such as ipilimumab and pembrolizumab. Preclinical development of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
